Daniel Gerlach, Associate Scientific Director, Computational Biology Oncology at Boehringer Ingelheim, posted on X about recent paper by him as co-author, titled “Pan-KRAS inhibitors BI-2493 and BI-2865 display potent anti-tumor activity in tumors with KRAS wild-type allele amplification” published on AACR Journals.

Authors: Antonio Tedeschi, Fiorella Schischlik, Francesca Rocchetti, Johannes Popow, Florian Ebner, Daniel Gerlach, Antonia Geyer, Valeria Santoro, Andrew S. Boghossian, Matthew G. Rees, Melissa M. Ronan, Jennifer A. Roth, Jesse Lipp, Matthias Samwer, Michael Gmachl, Norbert Kraut, Mark Pearson, Dorothea Rudolph

Daniel Gerlach: Pan-KRAS inhibitors displaying potent anti-tumor activity in tumors with KRAS allele amplification

“Excited to share our recent work on the pan-KRAS inhibitors BI-2493 and BI-2865, displaying potent anti-tumor activity in tumors with KRAS wild-type allele amplification.

Great team effort by Boehringer Ingelheim.”